Lizhi Stock Forecast, Price & News

Lizhi (NASDAQ:LIZI) Frequently Asked Questions

Is Lizhi a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lizhi in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lizhi stock.
View analyst ratings for Lizhi or view top-rated stocks.

How has Lizhi's stock been impacted by COVID-19 (Coronavirus)?

Lizhi's stock was trading at $8.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LIZI shares have decreased by 72.6% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19.

Are investors shorting Lizhi?

Lizhi saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,120,000 shares, an increase of 51.4% from the October 31st total of 739,600 shares. Based on an average trading volume of 553,300 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.0% of the company's shares are short sold.
View Lizhi's Short Interest.

When is Lizhi's next earnings date?

Lizhi is scheduled to release its next quarterly earnings announcement on Monday, November 29th 2021.
View our earnings forecast for Lizhi.

How can I listen to Lizhi's earnings call?

Lizhi will be holding an earnings conference call on Monday, November 29th at 8:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 855-452-5696 with passcode "7790167".

How were Lizhi's earnings last quarter?

Lizhi Inc. (NASDAQ:LIZI) posted its quarterly earnings data on Sunday, August, 29th. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.30) by $0.72. The company earned $86.62 million during the quarter. Lizhi had a negative net margin of 6.07% and a negative trailing twelve-month return on equity of 62.31%.
View Lizhi's earnings history.

What price target have analysts set for LIZI?

2 brokerages have issued twelve-month price targets for Lizhi's shares. Their forecasts range from $8.00 to $9.00. On average, they expect Lizhi's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 252.7% from the stock's current price.
View analysts' price targets for Lizhi or view top-rated stocks among Wall Street analysts.

Who are Lizhi's key executives?

Lizhi's management team includes the following people:

• Mr. Jinnan Lai, Founder, Chairman & CEO (Age 46)
• Mr. Ning Ding, Co-founder, CTO & Director (Age 42)
• Ms. Chengfang Lu, Acting Chief Financial Officer (Age 33)
• Mr. Zelong Li, COO & Director (Age 36)
• Ms. Juan Ren, VP & Director (Age 36)
• Effy Kang, Head of Capital Markets

Who are some of Lizhi's key competitors?

Some companies that are related to Lizhi include GAN (GAN), EverQuote (EVER), TrueCar (TRUE), KLDiscovery (KLDI), Qutoutiao (QTT), East Stone Acquisition (ESSC), Aurora Mobile (JG), Alithya Group (ALYA), Moxian (MOXC), Golden Path Acquisition (GPCO), Alfi (ALF), ZW Data Action Technologies (CNET), Oblong (OBLG), AutoWeb (AUTO) and Oblong (OBLG).
View all of LIZI's competitors.

What other stocks do shareholders of Lizhi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lizhi investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Lizhi IPO?

(LIZI) raised $49 million in an IPO on Friday, January 17th 2020. The company issued 4,100,000 shares at $11.00-$13.00 per share. Citigroup served as the underwriter for the IPO and Haitong International, AMTD, Needham, Tiger Brokers, China Merchants Securities (HK), Valuable Capital and Prime Number Capital were co-managers.

What is Lizhi's stock symbol?

Lizhi trades on the NASDAQ under the ticker symbol "LIZI."

Who are Lizhi's major shareholders?

Lizhi's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.05%), Atom Investors LP (0.82%), Renaissance Technologies LLC (0.65%), Marshall Wace LLP (0.30%), Millennium Management LLC (0.25%) and Citigroup Inc. (0.21%).

Which institutional investors are selling Lizhi stock?

LIZI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Atom Investors LP, Millennium Management LLC, Jane Street Group LLC, Citadel Advisors LLC, and Wolverine Trading LLC.

Which institutional investors are buying Lizhi stock?

LIZI stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Citigroup Inc., Marshall Wace LLP, MARSHALL WACE ASIA Ltd, Goldman Sachs Group Inc., BlackRock Inc., and Invesco Ltd..

How do I buy shares of Lizhi?

Shares of LIZI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lizhi's stock price today?

One share of LIZI stock can currently be purchased for approximately $2.41.

How much money does Lizhi make?

Lizhi has a market capitalization of $111.85 million and generates $230.33 million in revenue each year. The company earns $-12.60 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Lizhi have?

Lizhi employs 2,020 workers across the globe.

What is Lizhi's official website?

The official website for Lizhi is www.lizhi.fm.

Where are Lizhi's headquarters?

Lizhi is headquartered at YANGCHENG CREATIVE INDUSTRY ZONE NO.309 HUANGPU AVENUE MIDDLE, TIANHE DISTRICT GUANGZHOU F4, 510655.

How can I contact Lizhi?

Lizhi's mailing address is YANGCHENG CREATIVE INDUSTRY ZONE NO.309 HUANGPU AVENUE MIDDLE, TIANHE DISTRICT GUANGZHOU F4, 510655. The company can be reached via phone at 020 8381-8791 or via email at [email protected].